Amniotic Fluid Stem Cell Therapy for Diabetes

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for treating diabetes, such as insulin therapy and islet transplantation, face challenges including chronic complications, limited tissue supply, and the need for lifelong immune suppression, while stem cell differentiation techniques struggle with cell survival, proliferation, and ethical concerns, limiting their wide-scale application.

Innovation Solution

The use of mammalian amniotic fluid stem cells, which are differentiated into pancreatic-like cells using pancreatic differentiation factors like Pdx1, and administered to patients to treat diabetes, potentially offering a sustainable and ethical solution.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If islet transplantation is performed using cadaver donors, then insulin production is restored, but tissue supply is limited and immune suppression is required

Engineering Contradiction:

Improveinsulin production restorationVSAvoidtissue supply

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent utilizes the patient's own bone marrow stem cells to generate insulin-producing cells, eliminating the need for external tissue donors. The endogenous stem cells are harvested, differentiated in vitro, and transplanted back to the same patient, creating a self-sufficient cell source that bypasses tissue supply limitations

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

The patent changes the source parameter from exogenous cadaver donors to endogenous bone marrow stem cells. This parameter change transforms the limited tissue supply problem into a self-renewing cell source, where the patient's own stem cells can be repeatedly harvested and differentiated as needed

Inventive Principle:

Principle #35Parameter changes

2Reliability

If islet transplantation is performed using cadaver donors, then insulin production is restored, but lifelong immune suppression is required

Engineering Contradiction:

Improveinsulin production restorationVSAvoidimmune suppression duration

Core Design Contradiction:

ReliabilityVSDuration of action of moving object

Solution Approach 1:

By using the patient's own bone marrow stem cells as the source, the patent creates an autologous transplant that is immunologically compatible with the recipient. This eliminates the need for lifelong immune suppression therapy, as the body does not recognize its own cells as foreign

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

The patent extracts the problematic immune rejection issue by removing the foreign tissue component. Instead of transplanting allogeneic islets that trigger immune response, the procedure extracts and uses only the patient's own stem cells, thereby taking out the source of immunological conflict

Inventive Principle:

Principle #2Taking out (Extraction)

3Quantity of substance

If forced ex vivo expansion of human islets is performed, then cell supply is increased, but premature senescence and dedifferentiation occur

Engineering Contradiction:

Improvecell supplyVSAvoidcell function

Core Design Contradiction:

Quantity of substanceVSReliability

Solution Approach 1:

The patent segments the expansion process into controlled in vitro differentiation stages rather than forcing continuous ex vivo expansion of mature islets. Bone marrow stem cells are harvested and differentiated stepwise into insulin-producing cells under controlled conditions, avoiding the senescence that occurs with forced expansion of differentiated cells

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent performs preliminary differentiation of bone marrow stem cells into insulin-producing cells before transplantation. This preliminary action in a controlled in vitro environment allows cells to acquire the desired function before being implanted, avoiding the need for post-transplantation expansion that would cause senescence

Inventive Principle:

Principle #10Preliminary action

4Quantity of substance

If xenogeneic tissue such as porcine islets is used, then cell supply is increased, but immune suppression and retroviral infection risk increase

Engineering Contradiction:

Improvecell supplyVSAvoidimmune suppression and infection risk

Core Design Contradiction:

Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The patent eliminates the need for xenogeneic tissue by using the patient's own bone marrow stem cells. This self-service approach provides unlimited cell supply from an endogenous source that is immunologically compatible and free from retroviral contamination risks associated with animal tissues

Inventive Principle:

Principle #25Self-service

Data Source

PatentUS9056093B2Regeneration of pancreatic islets by amniotic fluid stem cell therapy

Publication Date: 2015.06.16 WAKE FOREST UNIVERSITY HEALTH SCIENCES INC

AI summary

A method of treating diabetes in a mammalian subject is carried out by: (a) providing mammalian amniotic fluid stem cells, and then (b) administering the cells to the subject in an amount effective to treat diabetes. Optionally, the cells may be differentiated into pancreatic-like cells or at least treated to initiate subsequent differentiation into-pancreatic-like cells, prior to administration.